Hi guys
You might have read Biophysia's rebuttal of Lipoxidil's critique of their Eucapil (fluridil) study - (if you haven't it's here)
Towards the end they make a passing insunation that RU trialling was dropped due to safety concerns over systemic absorption - here's the snippet:
"Furthermore, the absence of a full toxicological report on RU-58841 in any species and the lack of human clinical data has led us to the assumption that product development has been abandoned."
Well, I've just sent Biophysica an email with the following information so hopefully I'll get a response - if I do I'll let you guys know...
Philippe Ballero (President of Proskelia, the company that now owns RU) confirmed back in Feb '03 that RU58841 (re-named PSK 3841 by the new owners) was already in Phase IIa of *human* testing and that they were anticipating moving to Phase IIb next month i.e. October '03
What's more, Proskelia still positively publish the fact that clinical development of PSK 3841 is progressing well - see below -
Also, here's a summary of PSK 3841 taken from their website (http://www.proskelia.com/rd_32.htm)
---------------------------------------------------------------
Topical Anti-Androgen _ PSK3841
PSK 3841 is an innovative molecule with a unique mechanism of action for the treatment of androgen-dependent conditions, such as alopecia and acne.
In pre-clinical studies, it has shown promising activity in various animal models of acne, alopecia and hirsutism. The product has good systemic and dermal tolerance. In human clinical pharmacology, there was no systemic anti-androgenic activity and again good general and dermal tolerance.
PSK 3841 has completed several Phase I studies and is currently in Phase II for alopecia. A clinical proof of principle phase II study in acne is also ongoing.
This product is available for licensing.
---------------------------------------------------------------
Hope that clears things up a bit
You might have read Biophysia's rebuttal of Lipoxidil's critique of their Eucapil (fluridil) study - (if you haven't it's here)
Towards the end they make a passing insunation that RU trialling was dropped due to safety concerns over systemic absorption - here's the snippet:
"Furthermore, the absence of a full toxicological report on RU-58841 in any species and the lack of human clinical data has led us to the assumption that product development has been abandoned."
Well, I've just sent Biophysica an email with the following information so hopefully I'll get a response - if I do I'll let you guys know...
Philippe Ballero (President of Proskelia, the company that now owns RU) confirmed back in Feb '03 that RU58841 (re-named PSK 3841 by the new owners) was already in Phase IIa of *human* testing and that they were anticipating moving to Phase IIb next month i.e. October '03
What's more, Proskelia still positively publish the fact that clinical development of PSK 3841 is progressing well - see below -

Also, here's a summary of PSK 3841 taken from their website (http://www.proskelia.com/rd_32.htm)
---------------------------------------------------------------
Topical Anti-Androgen _ PSK3841
PSK 3841 is an innovative molecule with a unique mechanism of action for the treatment of androgen-dependent conditions, such as alopecia and acne.
In pre-clinical studies, it has shown promising activity in various animal models of acne, alopecia and hirsutism. The product has good systemic and dermal tolerance. In human clinical pharmacology, there was no systemic anti-androgenic activity and again good general and dermal tolerance.
PSK 3841 has completed several Phase I studies and is currently in Phase II for alopecia. A clinical proof of principle phase II study in acne is also ongoing.
This product is available for licensing.
---------------------------------------------------------------
Hope that clears things up a bit